Zila, Inc., a diagnostic company, engages in the prevention, detection, and treatment of oral cancer and periodontal disease. It manufactures and markets ViziLite Plus with TBlue, its flagship product, for early detection of oral abnormalities that could lead to cancer. In addition, the company designs, manufactures, and markets a suite of proprietary products directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler, and a portfolio of oral pharmaceutical products for in-office and home-care use. Further, it had certain technology rights, and the United States and foreign patent rights related to the OraTest, an oral cancer diagnostic product. Zila, Inc. markets and sells its products in the United States and Canada through direct sales force, and internationally through third party distributors. The company was founded in 1980 and is headquartered in Phoenix, Arizona. As of September 18, 2009, Zila, Inc. operates as a subsidiary of Tolmar, Inc.

Henderson Morley takes aim at those pesky microscopic parasites we know as viruses. The company researches and develops vaccines and treatments for viral infections by preventing them from replicating once they invade their host cells. One of its lead product candidates is a vaccine for genital herpes that could be used as a preventative or a therapeutic measure. Other candidates target human cytomegalovirus and human papillomavirus. Instead of taking its candidates through all phases of development, Henderson Morley instead looks to out-license its candidates. Chairman Andrew Knight owns 34% of the company.

Bioniche Life Sciences is seeking its niche in the development of drugs for both humans and animals. The firm has three divisions: Human Health, Animal Health, and Food Safety. The Bioniche Animal Health division sells products to improve livestock breeding and to boost livestock immunity without antibiotics. Bioniche's Food Safety division works to improve food and water quality by developing technology to prevent infections and diseases in animals that are passed on to humans. The company's Bioniche Therapeutics segment is developing pharmaceuticals to help humankind; it focuses on urology, oncology, and immune system disorders.

Peoplesway.Com, Inc., an electronic commerce and Internet services company, maintains an Internet destination called ‘Peoplesway’, located at www.peoplesway.com. The majority of the company’s goods and services are available through an alliance with DRM, Inc. and its member network of approximately 14,000 independent contractors. The Web site offers goods and services for sale, such as personal hygiene products, skin care, hair care, and bath products. In addition, DRM supplies Body Management System nutritional products, including weight loss and anti-aging supplements. DRM manufactures and packages these products through a licensing agreement with a health and beauty product manufacturer.

IDEXX Laboratories, Inc. company was founded in 1983 and is headquartered in Westbrook, Maine. IDEXX Laboratories, Inc. develops, designs, manufactures, and distributes products for veterinary, and food and water testing markets. It operates in three segments: Companion Animal Group (CAG), Water Quality Products (Water), and Production Animal Segment (PAS). The CAG segment provides point-of-care veterinary diagnostic products, such as instruments and consumables, and rapid assays; and information products and services, and digital radiography systems for veterinarians. This segment also offers commercial veterinary reference laboratory and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, and South Africa. The Water segment offers a range of products used in the detection of various microbiological analytes in water to government laboratories, water utilities, and private certified laboratories. The PAS segment provides diagnostic tests and related instrumentation that are used to detect diseases, and to monitor health status in production animals. This segment offers its products primarily to government laboratories, cattle, and poultry and swine producers. IDEXX Laboratories also provides products that test milk for antibiotic residues to dairy producers and processors, as well as to government and food-quality managers. In addition, the company sells point-of-care analyzers and related consumables for use in human medical hospitals and clinics to measure electrolytes, blood gases, acid-base balance, glucose, and ionized calcium, as well as to calculate other parameters, such as base excess and anion gap. It markets and sells its products directly, as well as through independent distributors and other resellers in the Americas, Europe, and the Asia Pacific region.

Formerly known as Stone Electronic Technology Limited, Stone Group Holdings Limited (Stock code: 409) was established on September 3, 1987. After a successful restructuring exercise in 1993, the Company became the first non-state-owned share-holding company in the PRC listed on the Stock Exchange of Hong Kong in August 1993. It is principally engaged in IT electronic & media – related business in mainland China, healthcare products business and investment business.The Company's IT electronic and media-related business includes the manufacture and distribution of traditional electronic products and the operation of internet café chain. Electronic products include dot matrix printer and value-added tax control machine with patented intellectual property, and the Group also acts as the agent and distributor of industrial controllers, uninterrupted power system equipment, digital graphics, semiconductors, computers etc.. Product coverage includes SIEMENS, FUJI. The internet café chain – Sunnet café is located in Guangdong Province.

Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland. Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology.

Acusphere, Inc. is a specialty pharmaceutical company that develops drugs and formulations of existing drugs using its porous microparticle technology. This technology enables the Company to control the size and porosity of particles, including nanoparticles and microparticles, so that the particles can be customized to address the delivery needs of a variety of drugs. These product candidates include Imagify (perflubutane polymer microspheres for delivery in an injectable suspension, formerly known as AI-700), a cardiovascular drug for the detection of coronary artery disease; Hydrophobic Drug Delivery System (HDDS), which converts drugs that do not dissolve well in water into microparticles or nanoparticles of the drugs embedded in small microparticles; and Pulmonary Drug Delivery System (PDDS).

Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California. Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin in Phase 3 trial program for the treatment of obesity; APD791, an anti-thrombotic drug candidate, which has completed Phase 1a and Phase 1b clinical trials; and APD125 that is in Phase 2b clinical trial for the treatment of insomnia. The company's clinical development programs also include APD597, an oral GPR119 agonist that is in Phase 1 clinical trial for the treatment of type 2 diabetes; APD916 drug candidate, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. Its drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including constitutively activated receptor technology and melanophore technology.

Cerus Corporation company was founded in 1991 and is based in Concord, California. Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company’s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. It has collaboration agreements with Baxter International, Inc., BioOne Corporation, and Laboratorios Grifols S.A., as well as the United States Armed Forces.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.